Condition: Hodgkin Lymphoma · Sponsor: St. Petersburg State Pavlov Medical University
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)
This description comes directly from the study's public registry record.
Polina Kotseliabina, MD · +78123386265 · md.FedorovaL@gmail.com
Liudmila Fedorova, MD, PhD · +78123386265 · md.FedorovaL@gmail.com
Always discuss trial participation with your own doctor first.
| National Research Oncology Center | Astana, Kazakhstan | Recruiting |
| National Medical and Surgical Center named after N.I. Pirogov | Moscow, Russia | Recruiting |
| RecruitingP. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation | Moscow, Russia | Recruiting |
| RM Gorbacheva Research Institute, Pavlov University | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06812858